The right comparison depends on the sleep problem, strength of the evidence and risks such as next-day impairment, interactions and uncertain product quality.
Key Takeaways
- Melatonin may be more relevant to jet lag, shift work and sleep timing than to chronic insomnia overall.
- Sedating antihistamines showed modest average benefits and can cause tolerance, grogginess and added risks for older adults.
- Prescription sleep medicines have drug-specific benefits and risks; Z-drugs carry a boxed warning for rare complex sleep behaviors.
- CBD is not FDA-approved for sleep, and a small pilot trial found no significant benefit on most sleep outcomes.
- Compare options according to the specific sleep problem, next-day impairment, interactions and product quality.
A useful sleep aids comparison starts with the reason you are not sleeping. A product that may help with jet lag or sleep timing is not necessarily an effective treatment for persistent insomnia. Likewise, a prescription medicine intended to reduce nighttime waking may not be the right choice for difficulty falling asleep.
Evidence also differs sharply across categories. Prescription insomnia medicines have drug-specific clinical data and regulated labeling, while evidence for over-the-counter antihistamines and melatonin in chronic insomnia is limited. CBD has not been approved by the U.S. Food and Drug Administration as a sleep treatment, and retail products add uncertainty about composition and quality.
Sleep aids comparison at a glance
- Melatonin: May be useful for jet lag, shift-work-related sleep problems or sleep timing. Evidence does not support it for every aspect of chronic insomnia, and long-term safety has not been established.
- Sedating antihistamines: Widely available in nonprescription sleep products, but their average benefits in chronic insomnia trials were small. Tolerance, next-day grogginess and risks for older adults are important limitations.
- Prescription sleep medicines: Some have stronger evidence for specific symptoms, such as trouble falling asleep or staying asleep. Risks vary by drug and include next-day impairment, confusion, memory problems and, for certain medicines, rare complex sleep behaviors.
- CBD: Not FDA-approved for sleep. Evidence remains limited, and possible concerns include drowsiness, liver injury, drug interactions and inconsistent retail products.
Melatonin: more relevant to sleep timing than to every form of insomnia
Melatonin is often grouped with general sleep aids, but its usefulness depends on the problem being treated. The National Center for Complementary and Integrative Health says it may help with jet lag, shift-work-related sleep problems and how quickly some people with insomnia fall asleep. That does not establish it as a broad treatment for chronic insomnia.
In the evidence reviewed by the American Academy of Sleep Medicine, 2 mg of melatonin reduced the time required to fall asleep by about nine minutes. The academy's 2017 guideline suggested that clinicians not use melatonin to treat chronic insomnia in adults. That was a weak recommendation based on the available evidence, not individualized medical advice.
Short-term melatonin use appears relatively safe, according to NCCIH, but long-term safety is not established. Supplement strength and purity can also vary. Families should store it securely: NCCIH cites an estimate of 11,000 emergency-department visits from 2019 through 2022 involving unsupervised melatonin ingestion by children age 5 or younger.
When melatonin may fit the question
Melatonin may be more relevant when jet lag, shift work or sleep timing is the main concern. Persistent trouble falling or staying asleep requires a different comparison because evidence for melatonin does not cover all aspects of chronic insomnia.
Antihistamine sleep aids: easy access, modest evidence and quick tolerance
Most nonprescription sleeping pills contain sedating antihistamines, according to MedlinePlus. Diphenhydramine is one example reviewed in the AASM guideline.
In those trials, 50 mg of diphenhydramine shortened sleep-onset time by about eight minutes and added about 12 minutes of total sleep, without improving sleep quality. These trial results are context, not dosing instructions. The guideline suggested that clinicians not use diphenhydramine for chronic insomnia in adults, although the recommendation was weak.
Tolerance can develop quickly, making an antihistamine less effective. Next-day grogginess is another concern. Older adults may be particularly vulnerable to memory and thinking problems, impaired balance and falls.
When an antihistamine may be a poor fit
Regular use for chronic insomnia is difficult to justify from the supplied evidence, especially if effectiveness is fading or daytime alertness, balance or cognition is affected. Age, other health conditions, alcohol use and concurrent sedating medicines can change the risk.
Prescription sleep pills: more targeted evidence, but more is not automatically better
Prescription sleep medicines are not interchangeable. A clinician may select one according to whether the main problem is sleep onset, sleep maintenance or both, while also considering medical history and other medications.
The AASM review found that results varied substantially by medicine and target symptom. In reviewed trials, doxepin increased total sleep time by about 26 to 32 minutes, while eszopiclone increased it by about 28 to 57 minutes. These findings should not be read as a head-to-head ranking, and trial doses or older dosing information should not be copied without checking current FDA labeling and consulting a clinician.
MedlinePlus identifies zolpidem, zaleplon, eszopiclone and ramelteon among commonly used prescription hypnotics. Possible adverse effects across prescription options can include daytime drowsiness, dizziness, confusion and memory problems, although the risks differ by medicine.
The boxed warning for Z-drugs
Eszopiclone, zaleplon and zolpidem carry an FDA boxed warning about rare complex sleep behaviors. These include activities such as walking, driving or cooking while not fully awake, which have led to serious injuries and deaths. The FDA says such events can occur after the first dose and at lower doses.
The agency advises against combining these Z-drugs with alcohol or other sleep medicines and warns about next-morning impairment. Anyone considering a prescription option should check current FDA information because labeling can change.
CBD for sleep: early research does not establish effectiveness
The FDA has not approved CBD as a sleep treatment, and there is no FDA-approved CBD dose for sleep. The only FDA-approved CBD medicine is indicated for specific seizure disorders, not insomnia.
A randomized pilot trial offers a limited picture. Thirty people with moderate-to-severe insomnia were assigned to either 150 mg of a standardized sublingual CBD product or placebo for two weeks. CBD was similar to placebo for insomnia severity, self-reported time to fall asleep, sleep efficiency and time awake after initially falling asleep. Objective sleep efficiency differed by 6.85 percentage points after two weeks, and some well-being measures improved, but most sleep outcomes did not.
The trial was small and short, so it cannot settle whether CBD is useful for insomnia. Its standardized 150 mg product should not be treated as equivalent to commercial gummies, oils or products combining CBD and THC.
CBD may cause drowsiness, diarrhea, appetite or mood changes, and the FDA warns about possible liver injury and drug interactions. Combining it with alcohol or medicines that slow brain activity can increase sedation and injury risk. Retail products may also have uncertain composition, labeling or contaminants.
How to compare the options before taking one
1. Define the sleep problem
- Jet lag, shift work or sleep timing: Melatonin has some relevant evidence, but that evidence should not be generalized to persistent insomnia.
- Trouble falling asleep: Compare evidence for sleep-onset effects rather than relying on a general claim that a product promotes sleep.
- Trouble staying asleep: Look for evidence on nighttime waking and total sleep time. A product aimed mainly at sleep onset may not address this problem.
- Chronic insomnia: The AASM guideline recommended against diphenhydramine and melatonin for this use, while suggesting certain prescription medicines for particular symptoms. All of those recommendations were weak and require individual clinical judgment.
2. Compare the size of the likely benefit
The trial averages help put marketing claims in perspective. In the AASM review, melatonin and diphenhydramine shortened sleep latency by less than 10 minutes on average, while some prescription-drug trials reported larger changes in total sleep time. These studies involved different medicines, outcomes and populations, so their numbers cannot be treated as a direct ranking.
3. Account for next-day safety
Antihistamines and prescription hypnotics can impair alertness the following day. CBD can also cause drowsiness, particularly when combined with alcohol or other substances that slow brain activity. Balance, memory and thinking problems are especially important considerations for older adults using sedating antihistamines.
4. Check interactions and product uncertainty
Alcohol and other sedating products can amplify impairment. CBD can interact with medicines, while nonprescription CBD and melatonin products may vary in composition or strength. A clinician or pharmacist can review the specific product alongside current medications and health conditions.
What This Means
There is no universal winner among melatonin, antihistamines, prescription pills and CBD. Melatonin has a clearer rationale for certain timing-related sleep problems than for chronic insomnia. Sedating antihistamines are accessible but provide modest average benefits and can quickly lose effectiveness. Prescription medicines may offer more targeted benefits, but selection and safety are drug-specific. CBD remains unapproved for sleep, with limited clinical evidence and additional product-quality uncertainty.
Before taking a sleep aid, identify whether the main issue is falling asleep, staying asleep or a disrupted schedule. Then weigh the evidence for that exact problem against next-day impairment, interactions and personal risk factors. For prescription medicines, persistent insomnia or combinations of sedating products, consult a clinician and check the latest official FDA information.
Sources
- American Academy of Sleep Medicine — Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults
- NIH National Center for Complementary and Integrative Health — Sleep Disorders and Complementary Health Approaches
- MedlinePlus — Medicines for Sleep
- U.S. Food and Drug Administration — Taking Z-drugs for Insomnia? Know the Risks
- U.S. Food and Drug Administration — What You Need to Know About Products Containing Cannabis or Cannabis-Derived Compounds, Including CBD
- Journal of Clinical Sleep Medicine — Randomized Pilot Trial of 150 mg Nightly CBD for Moderate-to-Severe Insomnia
